Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook 
Google to Move All Pixel Production Out of China by 2027 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Add as a preferred source on Google
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
